Peter Clark to Prostatic Neoplasms
This is a "connection" page, showing publications Peter Clark has written about Prostatic Neoplasms.
Connection Strength
3.918
-
Phillips JJ, Hall MC, Lee WR, Clark PE. Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? Urol Oncol. 2007 May-Jun; 25(3):196-200.
Score: 0.215
-
Clark PE, Hall MC, Borden LS, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R, Lovato J, Harmon M, Torti FM. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology. 2006 Jun; 67(6):1257-61.
Score: 0.202
-
Clark PE, Torti FM. Prostate cancer and bone metastases: medical treatment. Clin Orthop Relat Res. 2003 Oct; (415 Suppl):S148-57.
Score: 0.168
-
Clark PE, Irvine RA, Coetzee GA. The androgen receptor CAG repeat and prostate cancer risk. Methods Mol Med. 2003; 81:255-66.
Score: 0.159
-
Darst BF, Hughley R, Pfennig A, Hazra U, Fan C, Wan P, Sheng X, Xia L, Andrews C, Chen F, Berndt SI, Kote-Jarai Z, Govindasami K, Bensen JT, Ingles SA, Rybicki BA, Nemesure B, John EM, Fowke JH, Huff CD, Strom SS, Isaacs WB, Park JY, Zheng W, Ostrander EA, Walsh PC, Carpten J, Sellers TA, Yamoah K, Murphy AB, Sanderson M, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Kittles RA, Xu J, Stern MC, Chokkalingam AP, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Kibel AS, Klein EA, Goodman PJ, Stanford JL, Drake BF, Hu JJ, Clark PE, Blanchet P, Casey G, Hennis AJM, Lubwama A, Thompson IM, Leach RJ, Gundell SM, Pooler L, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Brureau L, Blot WJ, Biritwum R, Tay E, Truelove A, Niwa S, Tettey Y, Varma R, McKean-Cowdin R, Torres M, Jalloh M, Magueye Gueye S, Niang L, Ogunbiyi O, Oladimeji Idowu M, Popoola O, Adebiyi AO, Aisuodionoe-Shadrach OI, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Yeboah ED, Mensah JE, Anthony Adjei A, Diop H, Cook MB, Chanock SJ, Watya S, Eeles RA, Chiang CWK, Lachance J, Rebbeck TR, Conti DV, Haiman CA. A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. Eur Urol. 2022 May; 81(5):458-462.
Score: 0.149
-
Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 2001 Feb; 57(2):281-5.
Score: 0.139
-
Nanda JS, Awadallah WN, Kohrt SE, Popovics P, Cates JMM, Mirosevich J, Clark PE, Giannico GA, Grabowska MM. Increased nuclear factor I/B expression in prostate cancer correlates with AR expression. Prostate. 2020 09; 80(13):1058-1070.
Score: 0.134
-
Darst BF, Wan P, Sheng X, Bensen JT, Ingles SA, Rybicki BA, Nemesure B, John EM, Fowke JH, Stevens VL, Berndt SI, Huff CD, Strom SS, Park JY, Zheng W, Ostrander EA, Walsh PC, Srivastava S, Carpten J, Sellers TA, Yamoah K, Murphy AB, Sanderson M, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Yeager M, Petrovics G, Cullen J, Neslund-Dudas C, Kittles RA, Xu J, Stern MC, Kote-Jarai Z, Govindasami K, Chokkalingam AP, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Kibel AS, Klein EA, Goodman PJ, Drake BF, Hu JJ, Clark PE, Blanchet P, Casey G, Hennis AJM, Lubwama A, Thompson IM, Leach R, Gundell SM, Pooler L, Xia L, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Eeles RA, Brureau L, Chanock SJ, Watya S, Stanford JL, Mandal D, Isaacs WB, Cooney K, Blot WJ, Conti DV, Haiman CA. A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. Eur Urol. 2020 09; 78(3):316-320.
Score: 0.133
-
David SN, Arnold Egloff SA, Goyal R, Clark PE, Phillips S, Gellert LL, Hameed O, Giannico GA. MAGI2 is an independent predictor of biochemical recurrence in prostate cancer. Prostate. 2018 06; 78(8):616-622.
Score: 0.114
-
Conti DV, Wang K, Sheng X, Bensen JT, Hazelett DJ, Cook MB, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Stevens VL, Berndt SI, Huff CD, Wang Z, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Stern MC, Jarai ZK, Govindasami K, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann T, Drake BF, Hu JJ, Clark PE, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJM, Han Y, Lubwama A, Thompson IM, Leach R, Easton DF, Schumacher F, Van den Berg DJ, Gundell SM, Stram A, Wan P, Xia L, Pooler LC, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Srivastava S, Eeles RA, Carpten J, Kibel AS, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Klein EA, Brureau L, Stram DO, Watya S, Chanock SJ, Witte JS, Blot WJ, Henderson BE, Haiman CA. Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. J Natl Cancer Inst. 2017 08 01; 109(8).
Score: 0.109
-
Goldstein J, Goyal R, Roland JT, Gellert LL, Clark PE, Hameed O, Giannico GA. MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma: ?A Comparison With AMACR. Am J Clin Pathol. 2016 Sep; 146(3):294-302.
Score: 0.103
-
Goldstein J, Borowsky AD, Goyal R, Roland JT, Arnold SA, Gellert LL, Clark PE, Hameed O, Giannico GA. MAGI-2 in prostate cancer: an immunohistochemical study. Hum Pathol. 2016 06; 52:83-91.
Score: 0.099
-
Grabowska MM, Kelly SM, Reese AL, Cates JM, Case TC, Zhang J, DeGraff DJ, Strand DW, Miller NL, Clark PE, Hayward SW, Gronostajski RM, Anderson PD, Matusik RJ. Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia. Endocrinology. 2016 Mar; 157(3):1094-109.
Score: 0.098
-
Ritch CR, You C, May AT, Herrell SD, Clark PE, Penson DF, Chang SS, Cookson MS, Smith JA, Barocas DA. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology. 2014 Jun; 83(6):1309-15.
Score: 0.087
-
Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA, Matusik RJ. NF-?B gene signature predicts prostate cancer progression. Cancer Res. 2014 May 15; 74(10):2763-72.
Score: 0.087
-
Kaffenberger SD, Keegan KA, Bansal NK, Morgan TM, Tang DH, Barocas DA, Penson DF, Davis R, Clark PE, Chang SS, Cookson MS, Herrell SD, Smith JA. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J Urol. 2013 Feb; 189(2):507-13.
Score: 0.078
-
Davies JD, Aghazadeh MA, Phillips S, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Penson DF, Smith JA, Barocas DA. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol. 2011 Dec; 186(6):2221-7.
Score: 0.073
-
Stabler S, Koyama T, Zhao Z, Martinez-Ferrer M, Allen RH, Luka Z, Loukachevitch LV, Clark PE, Wagner C, Bhowmick NA. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One. 2011; 6(8):e22486.
Score: 0.072
-
Thompson IM, Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. World J Urol. 2011 Feb; 29(1):15-20.
Score: 0.069
-
Newton MR, Phillips S, Chang SS, Clark PE, Cookson MS, Davis R, Fowke JH, Herrell SD, Baumgartner R, Chan R, Mishra V, Blume JD, Smith JA, Barocas DA. Smaller prostate size predicts high grade prostate cancer at final pathology. J Urol. 2010 Sep; 184(3):930-7.
Score: 0.068
-
Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Wills ML, Shappell SB, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA. Comparative analysis of whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. J Urol. 2010 Oct; 184(4):1334-40.
Score: 0.068
-
Kordan Y, Barocas DA, Altamar HO, Clark PE, Chang SS, Davis R, Herrell SD, Baumgartner R, Mishra V, Chan RC, Smith JA, Cookson MS. Comparison of transfusion requirements between open and robotic-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Oct; 106(7):1036-40.
Score: 0.065
-
Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010 May-Jun; 60(3):194-201.
Score: 0.065
-
Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010 Feb 16; 121(6):833-40.
Score: 0.065
-
Barocas DA, Salem S, Kordan Y, Herrell SD, Chang SS, Clark PE, Davis R, Baumgartner R, Phillips S, Cookson MS, Smith JA. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. J Urol. 2010 Mar; 183(3):990-6.
Score: 0.065
-
Kordan Y, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA, Barocas DA. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol. 2009 Dec; 182(6):2695-701.
Score: 0.064
-
Kordan Y, Chang SS, Salem S, Cookson MS, Clark PE, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA, Barocas DA. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. J Urol. 2009 Nov; 182(5):2291-5.
Score: 0.063
-
Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO, Clark PE, Hu JJ, Ochoa AC. Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis. 2009 Aug; 30(8):1358-62.
Score: 0.062
-
Barocas DA, Patel SG, Chang SS, Clark PE, Smith JA, Cookson MS. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009 Oct; 104(8):1091-7.
Score: 0.062
-
Patel SG, Cookson MS, Barocas DA, Clark PE, Smith JA, Chang SS. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int. 2009 Oct; 104(7):934-7.
Score: 0.061
-
Lewis JE, Soler-Vilá H, Clark PE, Kresty LA, Allen GO, Hu JJ. Intake of plant foods and associated nutrients in prostate cancer risk. Nutr Cancer. 2009; 61(2):216-24.
Score: 0.060
-
Winterich JA, Grzywacz JG, Quandt SA, Clark PE, Miller DP, Acuña J, Dignan MB, Arcury TA. Men's knowledge and beliefs about prostate cancer: education, race, and screening status. Ethn Dis. 2009; 19(2):199-203.
Score: 0.060
-
Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA, Clark PE, Bhowmick NA. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res. 2008 Dec 01; 14(23):7790-7.
Score: 0.060
-
Rossi PJ, Urbanic J, Clark PE, McCullough DL, Lee WR. Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. Brachytherapy. 2008 Oct-Dec; 7(4):286-9.
Score: 0.059
-
Winterich JA, Quandt SA, Grzywacz JG, Clark PE, Miller DP, Acuña J, Arcury TA. Masculinity and the body: how African American and White men experience cancer screening exams involving the rectum. Am J Mens Health. 2009 Dec; 3(4):300-9.
Score: 0.059
-
Chan RC, Barocas DA, Chang SS, Herrell SD, Clark PE, Baumgartner R, Smith JA, Cookson MS. Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy. BJU Int. 2008 May; 101(9):1140-4.
Score: 0.058
-
Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor OA, Hu JJ, Ochoa AC. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis. 2008 Mar; 29(3):573-8.
Score: 0.056
-
Smith JA, Chan RC, Chang SS, Herrell SD, Clark PE, Baumgartner R, Cookson MS. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol. 2007 Dec; 178(6):2385-9; discussion 2389-90.
Score: 0.056
-
Yacoub J, Richardson C, Farmer M, Lee WR, Clark PE, Hurt G, Levine EA. Male breast cancer during treatment with leuprolide for prostate cancer. Clin Adv Hematol Oncol. 2007 Jul; 5(7):555-6; discussion 556-7.
Score: 0.054
-
Papagikos MA, Rossi PJ, Urbanic JJ, deGuzman AF, McCullough DL, Clark PE, Lee WR. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. Am J Clin Oncol. 2007 Apr; 30(2):199-204.
Score: 0.053
-
Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, M Mohler R, Torti FM. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Cancer. 2006 Sep 1; 107(5):1093-100.
Score: 0.051
-
Rackley JD, Clark PE, Hall MC. Complementary and alternative medicine for advanced prostate cancer. Urol Clin North Am. 2006 May; 33(2):237-46, viii.
Score: 0.050
-
Rossi PJ, Clark PE, Papagikos MA, McCullough DL, Lee WR. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urology. 2006 Feb; 67(2):349-53.
Score: 0.049
-
Lockett KL, Hall MC, Clark PE, Chuang SC, Robinson B, Lin HY, Su LJ, Hu JJ. DNA damage levels in prostate cancer cases and controls. Carcinogenesis. 2006 Jun; 27(6):1187-93.
Score: 0.049
-
Papagikos MA, Deguzman AF, Rossi PJ, McCullough DL, Clark PE, Lee WR. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? Brachytherapy. 2005; 4(4):252-8.
Score: 0.046
-
Lockett KL, Hall MC, Xu J, Zheng SL, Berwick M, Chuang SC, Clark PE, Cramer SD, Lohman K, Hu JJ. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res. 2004 Sep 01; 64(17):6344-8.
Score: 0.045
-
Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res. 2003 Mar; 1(5):385-92.
Score: 0.040
-
Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. J Natl Compr Canc Netw. 2009 Jan; 7(1):8-39.
Score: 0.015